Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Toxoplasmosis Treatment in Schizophrenia or Depression
NCT00300404Phase 3Completed
- Sponsor
- Zentrum für Integrative Psychiatrie
- Start
- Jan 2002
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of pyrimethamine in schizophrenia, major depressive disorder (MDD), sponsored by Zentrum für Integrative Psychiatrie. Started Jan 2002; status: completed.
02
Drugs
pyrimethamine
03
Conditions
schizophreniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00300404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00300404.